Olanow, C. Warren

MDS clinical diagnostic criteria for Parkinson’s disease

Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 7,653

Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 7,536

Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease

Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 1,722

International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study

Chaudhuri, K. R., Martinez‐Martin, P., Schapira, A. H. V., Stocchi, F., Sethi, K., Odin, P., Brown, R. G., Koller, W., Barone, P., MacPhee, G., et al. (2006) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 1,100

Oxidative stress and the pathogenesis of Parkinson's disease

Jenner, P., & Olanow, C. W. (1996) · Neurology

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 971

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsNeurology and Historical Studies

Cited by 859

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

Olanow, C. W., Kieburtz, K., Odin, P., Espay, A. J., Standaert, D. G., Fernandez, H. H., Vanagunas, A., Othman, A. A., Widnell, K. L., Robieson, W. Z., et al. (2014) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 716

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology

Virus-based gene therapy researchParkinson's Disease Mechanisms and Treatments

Cited by 596

Altered proteasomal function in sporadic Parkinson’s disease

St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology

Parkinson's Disease Mechanisms and TreatmentsUbiquitin and proteasome pathways

Cited by 573

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease

McNaught, K. S. P., Perl, D. P., Brownell, A., & Olanow, C. W. (2004) · Annals of Neurology

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 548

DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers

Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., et al. (2007) · Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 548

Protein Nitration in Parkinsonʼs Disease

Good, P. F., Hsu, A., Werner, P., Perl, D. P., & Olanow, C. W. (1998) · Journal of Neuropathology and Experimental Neurology

Parkinson's Disease Mechanisms and TreatmentsRedox biology and oxidative stress

Cited by 540

Failure of the ubiquitin-proteasome system in Parkinson’s disease

McNaught, K. S. P., Olanow, C. W., Halliwell, B., Isacson, O., & Jenner, P. (2001) · Nature Reviews Neuroscience

Parkinson's Disease Mechanisms and TreatmentsUbiquitin and proteasome pathways

Cited by 519

Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study

Good, P. F., Olanow, C. W., & Perl, D. P. (1992) · Brain Research

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 427

An introduction to the free radical hypothesis in Parkinson's disease

Olanow, C. W. (1992) · Annals of Neurology

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 382

Levodopa in the treatment of Parkinson's disease: Current controversies

Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 370

The basal ganglia in Parkinson's disease: Current concepts and unexplained observations

Obeso, J. A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Temiño, B., Mena-Segovia, J., Rodríguez, M., & Olanow, C. W. (2009) · Annals of Neurology

Deep Brain Stimulation and Movement DisordersParkinson's Disease Mechanisms and Treatments

Cited by 359

Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson’s disease

McNaught, K. S. P., & Olanow, C. W. (2003) · Annals of Neurology

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 203

Sleepiness in Parkinson's disease: A controlled study

Brodsky, M. A., Godbold, J., Roth, T., & Olanow, C. W. (2003) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsSleep and Work-Related Fatigue

Cited by 169

Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study

Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research

Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolism

Cited by 156

Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial

McGarry, A., Rosanbalm, S., Leinonen, M., Olanow, C. W., To, D., Bell, A., Lee, D., Chang, J., Dubow, J., Dhall, R., et al. (2024) · The Lancet Neurology

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 153

Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson’s disease

Olanow, C. W., Savolainen, M., Chu, Y., Halliday, G. M., & Kordower, J. H. (2019) · Brain

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 112

Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson’s disease

Chu, Y., Bartus, R. T., Manfredsson, F. P., Olanow, C. W., & Kordower, J. H. (2020) · Brain

Parkinson's Disease Mechanisms and TreatmentsVirus-based gene therapy research

Cited by 88